<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over a 2-year period, to evaluate the efficacy and safety of biologic agents, etanercept (25 mg twice per week, s.c.) was used to treat 57 <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) patients, 9 ankylosing <z:e sem="disease" ids="C0038012" disease_type="Disease or Syndrome" abbrv="">spondylitis</z:e> (AS) patients, 6 psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> (PSA) patients, and 4 <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JRA</z:e>) patients </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to inflammatory <z:hpo ids='HP_0001369'>arthritis</z:hpo>, I have used this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) blocker in other <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> including <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>), <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease with intractable <z:hpo ids='HP_0000155'>oral ulcer</z:hpo>, <z:e sem="disease" ids="C0016053" disease_type="Disease or Syndrome" abbrv="">fibromyalgia syndrome</z:e>, and <z:e sem="disease" ids="C0024141" disease_type="Disease or Syndrome" abbrv="">systemic lupus erythematosis</z:e> with intractable <z:hpo ids='HP_0002202'>pleural effusion</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> lumbar disc <z:e sem="disease" ids="C0019270" disease_type="Disease or Syndrome" abbrv="">herniation</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>For RA, after 6 months of etanercept treatment, <z:hpo ids='HP_0000001'>all</z:hpo> the parameters including number of swollen joints, number of tender joints, disease activity score, erythrocyte sedimentation rate, C-reactive protein, and global health status were rapidly improved (P &lt; 0.001 or P &lt; 0.0001) </plain></SENT>
<SENT sid="3" pm="."><plain>The anticyclic citrullinated <z:chebi fb="7" ids="16670">peptide</z:chebi> (anti-<z:chebi fb="97" ids="35889">CCP</z:chebi>) antibody and rheumatoid factor also significantly declined </plain></SENT>
<SENT sid="4" pm="."><plain>For <z:e sem="disease" ids="C0949691" disease_type="Disease or Syndrome" abbrv="SPDA1">spondyloarthropathy</z:e>, it also gave a similar effect as to RA </plain></SENT>
<SENT sid="5" pm="."><plain>Both Bath <z:e sem="disease" ids="C0038013" disease_type="Disease or Syndrome" abbrv="">Ankylosing Spondylitis</z:e> Disease Activity Index and Bath <z:e sem="disease" ids="C0038013" disease_type="Disease or Syndrome" abbrv="">Ankylosing Spondylitis</z:e> Functional Index also improved </plain></SENT>
<SENT sid="6" pm="."><plain>One of the two cases with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease with intractable <z:hpo ids='HP_0000155'>oral ulcer</z:hpo> had a long-term remission after etanercept </plain></SENT>
<SENT sid="7" pm="."><plain>The other <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease patient with <z:hpo ids='HP_0000155'>oral ulcer</z:hpo> and another with <z:chebi fb="0" ids="16039">ITP</z:chebi> obtained a good response temporarily </plain></SENT>
<SENT sid="8" pm="."><plain>The short-term use of etanercept (&lt;3 months) did not bring a significant effect for cases of <z:e sem="disease" ids="C0016053" disease_type="Disease or Syndrome" abbrv="">fibromyalgia syndrome</z:e>, <z:hpo ids='HP_0002202'>pleural effusion</z:hpo>, and lumbar disc <z:e sem="disease" ids="C0019270" disease_type="Disease or Syndrome" abbrv="">herniation</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, a dramatic and rapid clinical response in different kinds of <z:hpo ids='HP_0001369'>arthritis</z:hpo> patients can be achieved by etanercept </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, the TNF-alpha inhibitor also can treat other severe rheumatic-related symptoms </plain></SENT>
<SENT sid="11" pm="."><plain>In general, except for a few cases with <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and two cases with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, etanercept was safe in our <z:hpo ids='HP_0001369'>arthritis</z:hpo> patients </plain></SENT>
<SENT sid="12" pm="."><plain>We need to study a larger number of patients in order to better understand the efficacy and safety of etanercept </plain></SENT>
</text></document>